The New England Journal of Medicine is changing its conflict-of-interest standards for writers because of the difficulty of finding experts without financial interests in drugmakers, the New York Times said.
The journal will now allow writers of editorials and review articles to have a financial interest in a company that makes a product mentioned in the article, or in a competitor, provided the writer doesn’t receive payments of $10,000 a year or more from the stake or have stock options or patents interests in the company, the paper said.
Seifert Systems Invests in Energy Efficiency to Strengthen Operations
For manufacturers, energy is more than just another operating expense. It plays a critical role…
Learn More
The new policy matches those at other medical journals, the paper said.
Authors of original studies will continue to disclose the sponsor of the research and any possible conflict of interest resulting from financial ties to companies, the paper said.
Bloomberg News
